A medical oncologist is a physician who has extensive training and experience in the diagnosis and treatment of cancer. As your primary cancer doctor, your medical oncologist and hematologist is actively involved in all levels of your care. He or she:
Cancer Care Northwest offers complete medical oncology and hematology services, including:
Chemotherapy: Uses anticancer medicine to kill cancer.
Immunotherapy: Uses medicines to boost your immune system's ability to fight cancer.
Hormonal therapy: Reduces the level of hormones that some tumors need to grow.
Stem Cell Transplant: Replaces stem cells that were damaged during high-dose chemotherapy with your healthy stem cells.
Targeted therapy: Uses drugs to target and directly attack cancer cells.
Chemotherapy treatments are available at each of Cancer Care Northwest’s locations. Our medical oncology team includes eight board-certified, fellowship-trained physicians, nine nurse practitioners, and oncology nurses certified in chemotherapy administration. Our medical oncologists have extensive training and experience in the use of medicines and related medical procedures to fight cancer. They collaborate closely with other members of your care team—including your surgical oncologist and radiation oncologist—to ensure optimal results.
Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients With Early Stage TNBC-Phase I (B-STRONGER-I).
View DetailsA Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3).
View DetailsA Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer.
View DetailsA Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients with Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy.
View DetailsA Phase III, Open-label, Randomized, Multicenter Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
View DetailsA Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
View DetailsAn Open-Label, Multicenter, Phase II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Mosunetuzumab Monotherapy in Patients With Select B-Cell Malignancies
View DetailsStudy of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR).
View DetailsPhase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors.
View DetailsA study to collect clinical as well as genomic data on lung cancer patients in order to improve our understanding of thoracic malignancies in our community as well as disparities that may affect patient access to treatment.
View DetailsA Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE).
View DetailsA Phase II Study of the Safety, Tolerability and Antitumor Activity of Tucatinib in Combination With Eribulin and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer.
View DetailsA Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8).
View DetailsA Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab.
View DetailsA Phase 3, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02).
View DetailsA Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib.
View DetailsMulticenter Open Label Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients with Brain Metastasis due to HR+/Her2- Breast Cancer.
View DetailsThis study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.
View Details
